191 related articles for article (PubMed ID: 34159292)
1. COVID-19 vaccine failure in a patient on rituximab therapy.
Chilimuri S; Mantri N; Zahid M; Sun H
Rheumatol Adv Pract; 2021; 5(2):rkab038. PubMed ID: 34159292
[No Abstract] [Full Text] [Related]
2. Breakthrough SARS-CoV-2 infections and prediction of moderate-to-severe outcomes during rituximab therapy in patients with rheumatic and musculoskeletal diseases in the UK: a single-centre cohort study.
Md Yusof MY; Arnold J; Saleem B; Vandevelde C; Dass S; Savic S; Vital EM; Emery P
Lancet Rheumatol; 2023 Feb; 5(2):e88-e98. PubMed ID: 36712951
[TBL] [Abstract][Full Text] [Related]
3. Immunogenicity and safety of a fourth COVID-19 vaccination in rituximab-treated patients: an open-label extension study.
Mrak D; Simader E; Sieghart D; Mandl P; Radner H; Perkmann T; Haslacher H; Mayer M; Koblischke M; Hofer P; Göschl L; Kartnig F; Deimel T; Kerschbaumer A; Hummel T; Kornek B; Thalhammer R; Stiasny K; Winkler S; Smolen JS; Aberle JH; Aletaha D; Heinz LX; Bonelli M
Ann Rheum Dis; 2022 Dec; 81(12):1750-1756. PubMed ID: 35977809
[TBL] [Abstract][Full Text] [Related]
4. Analysis of Rituximab Use, Time Between Rituximab and SARS-CoV-2 Vaccination, and COVID-19 Hospitalization or Death in Patients With Multiple Sclerosis.
Smith JB; Gonzales EG; Li BH; Langer-Gould A
JAMA Netw Open; 2022 Dec; 5(12):e2248664. PubMed ID: 36576740
[TBL] [Abstract][Full Text] [Related]
5. Strong response after fourth dose of mRNA COVID-19 vaccine in autoimmune rheumatic diseases patients with poor response to inactivated vaccine.
Aikawa NE; Kupa LVK; Silva CA; Saad CGS; Pasoto SG; Yuki EFN; Fusco SRG; Shinjo SK; Andrade DCO; Sampaio-Barros PD; Pereira RMR; Chasin ACS; Shimabuco AY; Luppino-Assad AP; Leon EP; Lopes MH; Antonangelo L; Medeiros-Ribeiro AC; Bonfa E
Rheumatology (Oxford); 2022 Dec; 62(1):480-485. PubMed ID: 35639644
[TBL] [Abstract][Full Text] [Related]
6. Severe COVID pneumonia and undetectable B cells after vaccination in patients previously treated with rituximab: a case series.
Sakano T; Bittner EA; Chang MG
Postgrad Med; 2022 Mar; 134(2):239-243. PubMed ID: 35129061
[TBL] [Abstract][Full Text] [Related]
7. SARS CoV-2 vaccine AND rituximab. Comment on: "SARS CoV-2 vaccine AND rituximab, timing is probably a key for a better vaccine response" by Verhoeven Joint Bone Spine. 2021;88:105258.
Mungmunpuntipantip R; Wiwanitkit V
Joint Bone Spine; 2022 Jan; 89(1):105281. PubMed ID: 34600149
[No Abstract] [Full Text] [Related]
8. The impact of immunomodulating treatment on the immunogenicity of COVID-19 vaccines in patients with immune-mediated inflammatory rheumatic diseases compared to healthy controls. A Swedish nationwide study (COVID19-REUMA).
Frodlund M; Nived P; Chatzidionysiou A; Södergren A; Klingberg E; Bengtsson A; Hansson M; Olsson S; Pin E; Klareskog L; Kapetanovic MC
Vaccine; 2023 May; 41(20):3247-3257. PubMed ID: 37076360
[TBL] [Abstract][Full Text] [Related]
9. COVID-19 breakthrough infections in rheumatic diseases patients after vaccination.
Alshukairi AN; Al-Omari A; Albeity A; Alandijany TA; Hassan AM; El-Kafrawy SA; Dada A; Al Hroub MK; El-Saed A; Bissar LS; Daghmush RM; Al-Ghamdi SMG; Perlman S; Azhar EI; Halabi H
J Infect Public Health; 2022 Jun; 15(6):685-688. PubMed ID: 35623243
[TBL] [Abstract][Full Text] [Related]
10. Rituximab-treated rheumatic patients: B cells predict seroconversion after COVID-19 boost or revaccination in initial vaccine non-responders.
Ammitzbøll C; Kragh Thomsen M; Bøgh Andersen J; Jensen JMB; From Hermansen ML; Dahl Johannsen A; Larsen ML; Mistegaard CE; Mikkelsen S; Szabados F; Vils SR; Erikstrup C; Hauge EM; Troldborg A
Rheumatology (Oxford); 2023 Jul; 62(7):2544-2549. PubMed ID: 36445008
[TBL] [Abstract][Full Text] [Related]
11. Cellular and humoral responses after second and third SARS-CoV-2 vaccinations in patients with autoimmune diseases treated with rituximab: specific T cell immunity remains longer and plays a protective role against SARS-CoV-2 reinfections.
Egri N; Calderón H; Martinez R; Vazquez M; Gómez-Caverzaschi V; Pascal M; Araújo O; Juan M; González-Navarro EA; Hernández-Rodríguez J
Front Immunol; 2023; 14():1146841. PubMed ID: 37180097
[TBL] [Abstract][Full Text] [Related]
12. Immunogenicity and safety of two doses of SARS-CoV-2 mRNA vaccine in kidney transplant recipients with low-dose rituximab.
Takai S; Nishida H; Ito H; Fukuhara H; Nawano T; Narisawa T; Kanno H; Yagi M; Yamagishi A; Sakurai T; Naito S; Kato T; Morikane K; Tsuchiya N
Int J Urol; 2022 Nov; 29(11):1279-1286. PubMed ID: 35863901
[TBL] [Abstract][Full Text] [Related]
13. Considerations for the use of immunosuppression for the management of pemphigus during the COVID-19 pandemic with a focus on rituximab: Case reports from a single center experience in Australia.
Koszegi B; Stone C; Murrell DF
Front Med (Lausanne); 2023; 10():1149742. PubMed ID: 36999066
[TBL] [Abstract][Full Text] [Related]
14. Immune response to SARS-CoV-2 mRNA vaccination in multiple sclerosis patients after rituximab treatment interruption.
Gröning R; Dernstedt A; Ahlm C; Normark J; Sundström P; Forsell MNE
Front Immunol; 2023; 14():1219560. PubMed ID: 37575257
[TBL] [Abstract][Full Text] [Related]
15. SARS-COV-2 vaccine responses in renal patient populations.
Smith RM; Cooper DJ; Doffinger R; Stacey H; Al-Mohammad A; Goodfellow I; Baker S; Lear S; Hosmilo M; Pritchard N; Torpey N; Jayne D; Yiu V; Chalisey A; Lee J; Vilnar E; Cheung CK; Jones RB
BMC Nephrol; 2022 May; 23(1):199. PubMed ID: 35641961
[TBL] [Abstract][Full Text] [Related]
16. SARS CoV-2 vaccine AND rituximab, timing might be a key for a better vaccine response.
Verhoeven F; Lepiller Q; Hecquet S; Prati C; Wendling D
Joint Bone Spine; 2021 Dec; 88(6):105258. PubMed ID: 34481943
[No Abstract] [Full Text] [Related]
17. Could anti-CD20 therapy jeopardise the efficacy of a SARS-CoV-2 vaccine?
Houot R; Levy R; Cartron G; Armand P
Eur J Cancer; 2020 Sep; 136():4-6. PubMed ID: 32619884
[TBL] [Abstract][Full Text] [Related]
18. Predictors of low spike antibody response in patients with systemic rheumatic disease after an initial course of COVID-19 vaccination.
Whelan MG; Santacroce L; Masto L; Qian G; Kowalski E; Vanni K; Kanjilal S; Weinblatt ME; Sparks JA; Tedeschi SK
Clin Rheumatol; 2023 Jun; 42(6):1695-1700. PubMed ID: 36656454
[TBL] [Abstract][Full Text] [Related]
19. Seroconversion among rituximab-treated patients following SARS-CoV-2 vaccine supplemental dose.
Rose E; Magliulo D; Kyttaris VC
Clin Immunol; 2022 Dec; 245():109144. PubMed ID: 36220613
[TBL] [Abstract][Full Text] [Related]
20. Effect of Immunosuppressive Diseases and Rituximab Infusions on Allowing COVID-19 Infection to Relapse.
Prasad RM; Srivastava S; Wang E; Liu JZ; Gami R; Abdelgadir A; Sharma A; Rayamajhi S; Tikaria R
Perm J; 2021 Oct; 26(1):123-131. PubMed ID: 35609158
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
